Pharma Is in Democrats' Crosshairs. Are Devices?

Among the priorities appear to be examining FDA's drug-safety and premarket approval procedures and authorizing Medicare to haggle with drug companies over prices. (The latter is long overdue, in my opinion.) Another may be tightening regulation of the dietary supplement industry. Reforms concerning the device industry aren't mentioned specifically, and there has been some talk of small-business-friendly legislation, which would benefit quite a few device companies. But, especially where FDA policy is concerned, measures that start with pharma often make their way over to devices. Let's hope those who now control Congress understand that devices are not merely a subset of pharma and that policies concerning devices need separate and distinct consideration.